NIKKEI 225
37,628.48 -831.60 (-2.16%) HANG SENG
17,248.51 +47.24 (+0.27%) CRUDE OIL
82.87 +0.06 (+0.07%) GOLD FUTURES
2,332.30 -6.10 (-0.26%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,406.72 -2,027.31 (-3.79%)
Vertex Pharmaceuticals Incorporated (0QZU.L)
| Previous close | 405.06 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 2,907 |
| Market cap | 1.031B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 0.42 |
| EPS (TTM) | 9.48 |
| Earnings date | 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksVertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
PR NewswireVERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex's cell therapies for type 1 diabetes (T1D). TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies.
Insider Monkey10 Best Performing Biotech ETFs in 2024
In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]
